4//SEC Filing
DUGGAN ROBERT W 4
Accession 0001599298-25-000106
CIK 0001599298other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 4:55 PM ET
Size
10.7 KB
Accession
0001599298-25-000106
Insider Transaction Report
Form 4
DUGGAN ROBERT W
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-05-30−74,545→ 0 totalExercise: $2.64Exp: 2034-01-02→ Common Stock (74,545 underlying) - Exercise/Conversion
Common Stock
2025-05-30$2.64/sh+74,545$196,799→ 555,754,696 total
Holdings
- 10,199,776(indirect: By Trust)
Common Stock
- 25,457,666(indirect: By Trust)
Common Stock
- 31,000(indirect: By Spouse)
Common Stock
- 50,000(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]On May 30, 2025, the Reporting Person exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share. The Reporting Person did not sell the underlying shares.
- [F2]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- [F3]The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024.
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001055919
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 4:55 PM ET
- Size
- 10.7 KB